Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2011-10-06 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2011-10-06 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 27, 2011, for Galectin Therapeutics Inc. It includes a corporate overview presentation attached as Exhibit 99.1. The text explicitly states that the presentation is attached as slides and is a corporate overview. The document is short (3008 characters) and primarily serves to furnish information about the presentation rather than containing detailed financial data or a full report. The presence of a presentation slide deck as an exhibit and the nature of the content (corporate overview) aligns with an Investor Presentation filing. Therefore, the document is best classified as an Investor Presentation (IP).
2011-09-29 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Galectin Therapeutics Inc. It registers additional shares under the company's 2009 Incentive Compensation Plan. The text includes details about the registration fee, incorporation by reference of prior filings (10-K, 10-Q, 8-K), and legal indemnification provisions. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This is a capital markets filing related to securities registration, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a regulatory filing for securities registration. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers miscellaneous SEC filings that do not fit other categories such as annual reports or earnings releases.
2011-08-15 English
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock options or warrants. It includes details about securities to be registered, references to other filings like 10-K and 10-Q, and legal provisions about indemnification of officers and directors. It is not an annual report, earnings release, or any other financial report but a registration statement related to share issuance under employee plans. This fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed registration information, not just an announcement or certification, so it is not RPA or RNS.
2011-08-15 English
FORM 10-Q
Interim / Quarterly Report Q2 2011
2011-08-12 English
AMENDMENT
Major Shareholding Notification
2011-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.